Expres2ion Biotech Holding Ab · OMXSTO:EXPRS2
Expres2ion Biotech Holding Ab — Investor Presentation (October 2026)
9 slides from Expres2ion Biotech Holding Ab's investor presentation, Oct 7, 2026
Slide 1: Teaching the immune system to target HER2
Teaching the immune system to target HER2 ES2B - C001 Active immunotherapy for combination treatment in HER2 - expressing cancers 7 October 2026, Basel Bent U. Frandsen, CEO Nasdaq First North: EXPRS2 ExpreS2ion Biotech Holding AB Company reg. no. 559033 - 3729
Slide 2: ExpreS2ion's development foundation
ExpreS2ion’s development foundation A clinical - stage oncology asset built on a proven protein platform ES2B - C001 brings the ExpreS2 platform into clinical oncology. ExpreS2 protein platform A proprietary Drosophila S2 expression system for complex recombinant proteins and antigens. VLP immunothe
Slide 3: An add-on designed to extend the benefit of HER2 therapy
An add - on designed to extend the benefit of HER2 therapy An add - on opportunity alongside established HER2 - directed therapies with approximately €15B in annual global sales Current HER2 therapies ES2B - C001 • Validated HER2 targeting • Intended polyclonal Goal + → • Direct anti - tumour activi
Slide 4: ES2B-C001 displays the full extracellular domain of HER2
ES2B - C001 displays the full extracellular domain of HER2 Designed to induce antibodies against multiple HER2 epitopes HER2 protein (all 4 extra - cellular domains, i.e. 1 Produce the complete target 1 polyclonal effect) Phase III validated ExpreS2 produces the full extracellular domain of HER2 - E
Slide 5: Phase I: anti-HER2 antibody responses in patients
Phase I: anti - HER2 antibody responses in patients Titres increase during induction and remain elevated in available follow - up samples Phase I early observations 12 / 13 8 6 evaluable patients 5 with ≥2- fold rises in 3 anti - HER2 antibody titres 2 0 Weeks post 1 st dose 0 3 6 9 12 15 18 No dose
Slide 6: Preclinical antibodies show functional activity
Preclinical antibodies show functional activity Exploratory assays on antibodies from vaccinated NHPs suggest three distinct tumour - killing mechanisms. Preclinical antibody function supports further testing in patient samples. CDC, complement ADCP, phagocytosis ADCC, cytotoxicity WHAT COMES NEXT D
Slide 7: Phase II is built to answer one question: does ES2B-C001 add clinical benefit?
Phase II is built to answer one question: does ES2B - C001 add clinical benefit? Planning direction: Detailed design to follow the Phase I readout Study direction ES2B - C001 plus a HER2 treatment backbone compared with the backbone alone Population and size 80 – 120 patients in total Earlier - line
Slide 8: Development partnerships towards Phase II
Development partnerships towards Phase II The next investment milestone is the integrated Phase I package YEAR END - 2026 H1 2027 H2 2027 TARGET PARTNERING NEEDS Integrated readout Phase II preparation Phase II initiation HER2 franchise owners: a combination partner for Phase II, with ES2B - C001 ad
Slide 9: Important information
Important information APPENDIX · NOT PRESENTED Forward - looking statements This presentation contains forward - looking statements, including statements regarding clinical development, data readouts, timelines, future studies, partnering and commercial opportunities. Such statements are based on cu
ExpreS2ion Biotech Holding — Investor Presentation (October 2026) on 6ix